Optimism in the treatment of Alzheimer's disease.
作者信息
Carrier L
出版信息
J Psychiatry Neurosci. 1999 Nov;24(5):398-401.
Abstract
摘要
相似文献
1
Optimism in the treatment of Alzheimer's disease.
J Psychiatry Neurosci. 1999 Nov;24(5):398-401.
2
Drugs to treat Alzheimer's disease.
J Psychosoc Nurs Ment Health Serv. 2009 Apr;47(4):13-4.
3
Methodological concerns: evaluating central nervous system (CNS) active compounds in Alzheimer's disease (AD).
Prog Clin Biol Res. 1989;317:1311-7.
4
[Pharmacological treatment of primary degenerative dementia].
Pol Tyg Lek. 1988 Feb 8;43(6):194-7.
5
Dog from hell chases Alzheimer's.
Nat Biotechnol. 1997 Apr;15(4):311. doi: 10.1038/nbt0497-311a.
6
[Therapy of Alzheimer dementia. Current status and prospects].
MMW Fortschr Med. 2000 Jun 22;142(25):30-4.
7
Alzheimer's centennial legacy: prospects for rational therapeutic intervention targeting the Abeta amyloid pathway.
Brain. 2006 Nov;129(Pt 11):2823-39. doi: 10.1093/brain/awl251. Epub 2006 Sep 29.
8
Alzheimer's disease.
Clin Symp. 1996;48(3):2-32.
9
A group of potassium-channel blockers-acetylcholine releasers: new potentials for Alzheimer disease? A review.
J Clin Psychopharmacol. 1992 Apr;12(2):110-8.
10
Commentary on "Alzheimer's disease drug development and the problem of the blood-brain barrier." Alzheimer's disease drugs: more than one barrier to breach.
Alzheimers Dement. 2009 Sep;5(5):437-8. doi: 10.1016/j.jalz.2009.07.037.
本文引用的文献
1
Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Drug Saf. 1998 Dec;19(6):465-80. doi: 10.2165/00002018-199819060-00004.
2
Current status of antioxidant therapy for Alzheimer's Disease.
J Am Geriatr Soc. 1998 Dec;46(12):1566-72. doi: 10.1111/j.1532-5415.1998.tb01544.x.
3
Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials.
Dement Geriatr Cogn Disord. 1998 Jul;9 Suppl 1:36-43. doi: 10.1159/000051188.
4
Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer's disease.
Neurology. 1998 May;50(5):1222-30. doi: 10.1212/wnl.50.5.1222.
5
Metrifonate treatment of the cognitive deficits of Alzheimer's disease. Metrifonate Study Group.
Neurology. 1998 May;50(5):1214-21. doi: 10.1212/wnl.50.5.1214.
6
Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: an interim analysis of the results of a US multicentre open label extension study.
Eur Neuropsychopharmacol. 1998 Feb;8(1):67-75. doi: 10.1016/s0924-977x(97)00079-5.
7
A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Donepezil Study Group.
Neurology. 1998 Jan;50(1):136-45. doi: 10.1212/wnl.50.1.136.
8
A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study.
N Engl J Med. 1997 Apr 24;336(17):1216-22. doi: 10.1056/NEJM199704243361704.
9
Intracranial infusion of purified nerve growth factor to an Alzheimer patient: the first attempt of a possible future treatment strategy.
Behav Brain Res. 1993 Nov 30;57(2):255-61. doi: 10.1016/0166-4328(93)90141-c.
10
Use of THA in treatment of Alzheimer-like dementia: pilot study in twelve patients.
Biol Psychiatry. 1981 Feb;16(2):145-53.
Zotero 插件